Platform trials are multi-arm studies that allow experimental agents to enter and exit a study over time. Sharing a control arm can provide efficiency gains in terms of a smaller total sample size. Many trialists have recommended platform trials for COVID-19 treatment studies largely due to their potential to reach conclusions faster. However, not all platform trials are created equally. Important design choices that alter study rigor include study endpoints, whether to use a placebo, whether to use response-adaptive randomization, whether to allow comparisons with nonconcurrent controls, how many agents to study, and when to drop/add study agents. In this talk, I will provide a framework to critically evaluate study design decisions behind COVID-19 treatment trials. This framework will be applied to the major trials as a way to rank quality of study results.